We are live on ! Find out more
ASBPW

Aspire Biopharma Warrant
ASBPW

29 hedge funds and large institutions have $251K invested in Aspire Biopharma Warrant in 2025 Q3 according to their latest regulatory filings, with 3 funds opening new positions, 4 increasing their positions, 0 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

50% more first-time investments, than exits

New positions opened: 3 | Existing positions closed: 2

32.05% more ownership

Funds ownership: 0% → 32.05% (+32%)

0% more funds holding

Funds holding: 29 → 29 (0)

38% less capital invested

Capital invested by funds: $408K → $251K (-$157K)

Holders
29
Holders Change
–
Holders Change %
0%
% of All Funds
0.38%
Holding in Top 10
1
Holding in Top 10 Change
+1
Holding in Top 10 Change %
% of All Funds
0.01%
New
3
Increased
4
Reduced
–
Closed
2
Calls
$8K
Puts
–
Net Calls
+$8K
Net Calls Change
-$4K

Top Buyers

Rank Fund Capital Flow
1
AC
Antara Capital
New York
+$10.5K
2
CS
Clear Street
New York
+$5.37K
3
Susquehanna International Group
Susquehanna International Group
Pennsylvania
+$2.93K
4
CA
Crossingbridge Advisors
New York
+$2.52K
5
WAM
Wolverine Asset Management
Illinois
+$61

Top Sellers

Rank Fund Capital Flow
1
TCA
Taconic Capital Advisors
New York
-$13.4K
2
AC
Athos Capital
Hong Kong
-$6K
Name Holding Trade Value Shares
Change 		Change in
Stake
Adage Capital Partners
1
Adage Capital Partners
Massachusetts
$31.4K – – –
SCM
2
Saba Capital Management
New York
$29.4K – – –
LA
3
Linden Advisors
New York
$25.2K – – –
AC
4
Aristeia Capital
Connecticut
$19K – – –
HCM
5
Highbridge Capital Management
New York
$16.6K – – –
Toronto Dominion Bank
6
Toronto Dominion Bank
Ontario, Canada
$15.5K +$5 +100 +0%
SC
7
Sculptor Capital
New York
$14K – – –
CS
8
Clear Street
New York
$13.1K +$5.37K +106,200 +32%
Verition Fund Management
9
Verition Fund Management
Connecticut
$12.9K – – –
Barclays
10
Barclays
United Kingdom
$10.5K – – –
AC
11
Antara Capital
New York
$6.21K +$10.5K +207,693 New
D.E. Shaw & Co
12
D.E. Shaw & Co
New York
$5.98K – – –
WAM
13
Wolverine Asset Management
Illinois
$5.89K +$61 +1,200 +0.6%
CCM
14
Context Capital Management
California
$5.23K – – –
MTCM
15
Mint Tower Capital Management
Netherlands
$5K – – –
Nomura Holdings
16
Nomura Holdings
Japan
$4.5K – – –
PAMP
17
Polar Asset Management Partners
Ontario, Canada
$3.88K – – –
LP
18
LMR Partners
United Kingdom
$3.74K – – –
PC
19
Periscope Capital
Ontario, Canada
$3.73K – – –
WA
20
Whitebox Advisors
Minnesota
$3.55K – – –
JP Morgan Chase
21
JP Morgan Chase
New York
$2.99K – – –
VAS
22
VR Advisory Services
Cayman Islands
$2.98K – – –
CA
23
Crossingbridge Advisors
New York
$2.79K +$2.52K +49,846 New
LIA
24
Limestone Investment Advisors
New York
$2.24K – – –
Susquehanna International Group
25
Susquehanna International Group
Pennsylvania
$1.73K +$2.93K +57,932 New
1
2

ASBPW Hedge Fund Activity: Q3 2025 in Review

29 of the 7,626 institutional investors tracked by Wall St. Rank reported a position in Aspire Biopharma Warrant (ASBPW) for Q3 2025, worth a combined $251K — down 38% from $408K a quarter earlier.

Buyers outnumbered sellers: 3 funds opened new ASBPW positions and 2 closed out — a net gain of 1 holder — while 4 added to existing stakes and 0 trimmed.

The largest buyer was Antara Capital, opening a new position worth an estimated $10.5K. The largest seller was Taconic Capital Advisors, exiting entirely with an estimated $13.4K sold.

  • 29 institutional investors held Aspire Biopharma Warrant (ASBPW) as of Q3 2025, unchanged from Q2 2025.
  • Funds reported $251K of Aspire Biopharma Warrant stock for Q3 2025, down 38% quarter-over-quarter.
  • 3 funds opened new Aspire Biopharma Warrant positions in Q3 2025 and 2 closed out, a net change of +1 holder.
  • The largest Aspire Biopharma Warrant buyer in Q3 2025 was Antara Capital, an estimated $10.5K added.
  • The largest Aspire Biopharma Warrant seller in Q3 2025 was Taconic Capital Advisors, an estimated $13.4K sold.

Based on aggregated 13F filings for Q3 2025.